N Stefan, K Kantartzis, HU Haring - Endocrine Reviews, 2008 - Endocrine Soc Type 2 diabetes and cardiovascular disease represent a serious threat to the
health of the population worldwide. Although overall adiposity and particularly
visceral adiposity are established risk factors for these diseases, in the ... Cited by 15 - Related articles - All 4 versions
- ►endojournals.org I Dostalova, P Kavalkova, D Haluzikova, Z … - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Context: Fibroblast growth factor 19 (FGF19) and FGF21 are novel metabolic
regulators that improve insulin sensitivity and decrease adiposity in mice.
However, little is known about the nutritional regulation of these factors ... Cited by 9 - Related articles - All 3 versions
K Oishi, D Uchida, N Ishida - FEBS letters, 2008 - Elsevier Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor
that regulates the expression of genes associated with lipid metabolism. Recent
studies have suggested that the expression of PPARα-dependent fibroblast ... Cited by 7 - Related articles - All 5 versions
R Micanovic, DW Raches, JD Dunbar, DA … - J Cell Physiol, 2009 - interscience.wiley.com Fibroblast growth factor 21 is a member of endocrine FGFs subfamily, along with
FGF19 and FGF23. It is emerging as a novel regulator with beneficial effects on
a variety of metabolic parameters, including glucose and lipid control. ... Cited by 5 - Related articles - All 2 versions
H Li, Y Bao, A Xu, X Pan, J Lu, H Wu, H Lu, K … - Journal of Clinical Endocrinology & Metabolism, 2009 - Endocrine Soc Design: Serum FGF21 levels were determined by ELISA in 134 normal glucose
tolerance (NGT), 101 isolated-impaired fasting glucose, and 118
isolated-impaired glucose tolerance (I-IGT) Chinese subjects, and their ... Cited by 3 - Related articles - All 3 versions
ED Berglund, CY Li, HA Bina, SE Lynes, MD … - Endocrinology, 2009 - Endocrine Soc Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator shown to
improve glycemic control. However, the molecular and functional mechanisms
underlying FGF21-mediated improvements in glycemic control are not ... Cited by 2 - Related articles - All 3 versions
M León-Latre, P Mazón-Ramos, E Marcos, E … - Rev Esp Cardiol, 2009 - revespcardiol.org En este artículo se revisan los principales avances publicados en la
prevención de las enfermedades cardiovasculares en el último año, así como
los nuevos documentos de consenso. Como en años precedentes, buena parte ... Cited by 2 - Related articles - Cached - All 5 versions
C Christodoulides, P Dyson, D Sprecher, K … - Journal of Clinical Endocrinology & Metabolism, 2009 - Endocrine Soc 1 Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital,
Oxford, UK. 2 NIHR Oxford Biomedical Research Centre, ORH Trust, Churchill
Hospital, Oxford, UK 3 Cardiovascular and Urogenital Centre for Excellence ... Cited by 1 - Related articles - All 2 versions
M Rydén - Cellular and Molecular Life Sciences, 2009 - Springer Abstract Fibroblast growth factor 21 (FGF21) has been proposed as a novel
putative therapeutic agent in type 2 diabetes. A large amount of data,
predominantly obtained from murine models but also from non-human primates, ... Cited by 1 - Related articles - All 2 versions
S Stein, A Bachmann, U Lössner, J Kratzsch, … - Diabetes Care, 2009 - Am Diabetes Assoc OBJECTIVE—To investigate renal elimination of the adipokine fibroblast growth
factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic
hemodialysis (CD) as compared with control subjects with a glomerular ... Cited by 1 - Related articles - All 3 versions
